| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/17/2009 | WO2009079452A3 Treatment and prevention of hiv infection |
| 09/17/2009 | WO2009077731A3 Prolactin fusion proteins |
| 09/17/2009 | WO2009075882A9 Impaired wound healing compositions and treatments |
| 09/17/2009 | WO2009071850A8 Nanoparticles of therapeutic agents having low water solubility |
| 09/17/2009 | WO2009059054A3 Bacteria strains an d bacteriocin produced therefrom |
| 09/17/2009 | WO2009046867A3 Caerulein alone or in combination with acth (3-24 ) as therapeutic agent |
| 09/17/2009 | WO2009046866A3 Trap-14 as a therapeutic agent |
| 09/17/2009 | WO2009043940A3 Peptides with high affinity for the prolactin receptor |
| 09/17/2009 | WO2009040070A3 Use of helodermin as a therapeutic agent |
| 09/17/2009 | WO2009019531A3 Bioactive peptides and method of using same |
| 09/17/2009 | WO2008101179A8 Use of sucrose to suppress mannitol-induced protein aggregation |
| 09/17/2009 | WO2008084368A8 Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
| 09/17/2009 | WO2007014167A3 Compositions for and methods of treating epithelial diseases with growth factors |
| 09/17/2009 | WO2004039335A3 Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor |
| 09/17/2009 | WO2003007876A3 N-fatty acid-amino acid conjugates and therapeutic uses |
| 09/17/2009 | WO2001085908A9 Clasp-1 transmembrane protein |
| 09/17/2009 | US20090234103 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
| 09/17/2009 | US20090234101 Directed evolution of novel binding proteins |
| 09/17/2009 | US20090234070 Water-Soluble Polymer Alkanals |
| 09/17/2009 | US20090233992 Hepatitis c virus vaccine |
| 09/17/2009 | US20090233873 Nitric oxide donors |
| 09/17/2009 | US20090233872 Therapeutic Agent for Neurodegenerative Disease |
| 09/17/2009 | US20090233871 Complexed polypeptide and adjuvant for improved vaccines |
| 09/17/2009 | US20090233870 Antimicrobial Peptides |
| 09/17/2009 | US20090233869 Psi-epsilon rack peptide composition and method for protection against tissue damage due to ischemia |
| 09/17/2009 | US20090233868 Small antiviral peptides against hepatitis C virus |
| 09/17/2009 | US20090233867 Treatment of ocular wounds and ulcers |
| 09/17/2009 | US20090233866 Screening Methods And The Use Of Agents Identified Using The Same |
| 09/17/2009 | US20090233865 Nutritional Compositions |
| 09/17/2009 | US20090233864 Novel antibiotic alternatives |
| 09/17/2009 | US20090233863 Hgf preparation |
| 09/17/2009 | US20090233862 Compositions and methods for treatment of optic nerve diseases |
| 09/17/2009 | US20090233861 Lytic domain fusion constructs and methods of making and using same |
| 09/17/2009 | US20090233860 Lytic domain fusion constructs and methods of making and using same |
| 09/17/2009 | US20090233859 modulating hepcidin and disease of iron metabolism such as hemochromatosis and anemia of chronic disease; adminstering soluble mammalian hemojuvelin protein |
| 09/17/2009 | US20090233858 Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation |
| 09/17/2009 | US20090233857 Dna vaccine compositions and methods of use |
| 09/17/2009 | US20090233856 Synthetic mecp2 sequence for protein substitution therapy |
| 09/17/2009 | US20090233855 Compounds and methods for modulating activation of nf-kb |
| 09/17/2009 | US20090233854 Novel application of apelin |
| 09/17/2009 | US20090233853 Use of outer membrane protein a in treatment/prevention/diagnosis of bacterial infection in central nervous system and/or peripheral blood circulation |
| 09/17/2009 | US20090233852 Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof |
| 09/17/2009 | US20090233851 Insulin Resistance Improver |
| 09/17/2009 | US20090233850 CVN-12p1: a recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions |
| 09/17/2009 | US20090233849 Recombinant Alpha-Fetoprotein, Method and Means for Preparation Thereof, Compositions on the Base Thereof and Use Thereof |
| 09/17/2009 | US20090233848 Pea15 as a Tumor Suppressor Gene |
| 09/17/2009 | US20090233847 Coupling Proteins to a Modified Polysaccharide |
| 09/17/2009 | US20090233846 Human luteinizing hormone superagonists |
| 09/17/2009 | US20090233845 Methods and compositions for non-covalently enhanced receptor binding |
| 09/17/2009 | US20090233844 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| 09/17/2009 | US20090233843 Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
| 09/17/2009 | US20090233842 Fgf2-related methods for diagnosing and treating depression |
| 09/17/2009 | US20090233841 Analgesic conjugates |
| 09/17/2009 | US20090233840 Modified Dynorphin Expression in Animals and Identification of Compounds for Treatment of Obesity and Diabetes |
| 09/17/2009 | US20090233368 Allele suppression |
| 09/17/2009 | US20090233317 Repressor of skeletal muscle differentiation, nucleic acids coding therefor and the use thereof in diagnosis and therapy |
| 09/17/2009 | US20090233315 Melanoma-associated antigen C2 (MAGE-C2); for provoking a cytolytic T cell response; for determining if a cell presents a Human Leukocyte Antigen(HLA) molecule on its surface; diagnostic and therapeutic assays; tumor monitoring |
| 09/17/2009 | US20090233286 Methods of diagnosis and prognosis of pancreatic cancer |
| 09/17/2009 | US20090233270 Secreted and cytoplasmic tumor endothelial markers |
| 09/17/2009 | US20090232911 Use of sericin for improving feeling in use of denture |
| 09/17/2009 | US20090232910 Biomarkers and therapeutics targets for cognitive decline |
| 09/17/2009 | US20090232909 Method for determining physiological effects of hemoglobin |
| 09/17/2009 | US20090232899 Mucoadhesive nanocomposite delivery system |
| 09/17/2009 | US20090232891 Cell Transport Compositions and Uses Thereof |
| 09/17/2009 | US20090232890 Compositions and methods for distraction osteogenesis |
| 09/17/2009 | US20090232886 Oral dosage combination pharmaceutical packaging |
| 09/17/2009 | US20090232882 PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCER |
| 09/17/2009 | US20090232878 Artificial Skin Substitute |
| 09/17/2009 | US20090232876 Method and composition for in situ formation of an artificial blockage to control bleeding |
| 09/17/2009 | US20090232870 Apparatus and method of retaining and releasing molecules from nanostructures by an external stimulus |
| 09/17/2009 | US20090232866 Oligopeptides as coating material for medical products |
| 09/17/2009 | US20090232865 End-Capped Poly(Ester Amide) Copolymers |
| 09/17/2009 | US20090232853 Treatment of laminitis |
| 09/17/2009 | US20090232852 Use of outer membrane protein a (ompa) in treatment/prevention/diagnosis of infections caused by klebsiella pneumoniae and other gram-negative bacteria |
| 09/17/2009 | US20090232842 HPV Vaccine Comprising Peptides From Host Cell Proteins |
| 09/17/2009 | US20090232839 Glycoprotein-100 peptide for use as tool in treatment and diagnosis of cancer and viral infection |
| 09/17/2009 | US20090232838 Ligands of melanocortin receptors |
| 09/17/2009 | US20090232835 Composition for delivery of hematopoietic growth factor |
| 09/17/2009 | US20090232830 Modified HIV-1 Envelope Proteins |
| 09/17/2009 | US20090232829 Methods and compositions for treating inflammatory conditions |
| 09/17/2009 | US20090232827 Compositions and methods of use of compounds to increase cancer patient survival time |
| 09/17/2009 | US20090232825 Methods and Compositions For Modulating Immunity |
| 09/17/2009 | US20090232822 Lung disease targets and uses thereof |
| 09/17/2009 | US20090232821 Use Of A Growth-Stimulating Protein |
| 09/17/2009 | US20090232820 Neisseria meningitidis antigens and compositions |
| 09/17/2009 | US20090232819 Method using snail transcriptional repressor |
| 09/17/2009 | US20090232815 Monoclonal antibody or antibody fragment which binds a pleiotrophin-binding fragment of human Anaplastic Lymphoma Kinase (ALK) and inhibits a pleiotrophin-mediated activity; prevents pleiotrophin-mediated neoplastic or mitogenic activity |
| 09/17/2009 | US20090232814 Cancer biomarker genes and gene products and methods for using the same |
| 09/17/2009 | US20090232812 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 09/17/2009 | US20090232809 Type 2 cytokine receptor and nucleic acids encoding same |
| 09/17/2009 | US20090232808 Molecules and chimeric molecules thereof |
| 09/17/2009 | US20090232800 E1-minus adenoviruses and use thereof |
| 09/17/2009 | US20090232793 Elastase inhibitor and acute leukemia |
| 09/17/2009 | US20090232791 comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein components are comprised in separate sterile containers |
| 09/17/2009 | US20090232790 Kit of Lyophilized Thrombin and Lyophilized Fibrinogen Used to Compound Fibrin Membrane, and Its Application |
| 09/17/2009 | US20090232789 Novel pharmaceutical preparation for preeclampsia, eclampsia, and toxemia, and their related symptoms and related disorders of pregnancy |
| 09/17/2009 | US20090232788 Enzyme With Microbial Lysis Activity From Trichoderma Reesei |
| 09/17/2009 | US20090232787 Carcinogen detoxification composition and method |
| 09/17/2009 | US20090232786 Herbal composition for cancer treatment |
| 09/17/2009 | US20090232775 Compounds and methods for increasing neurogenesis |